Modulation of Hyperinflammation in COVID-19

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

December 30, 2023

Study Completion Date

March 15, 2024

Conditions
COVID-19SARS
Interventions
DEVICE

Control group

Patients randomized into this group will receive standard of care for COVID-19 infection

DEVICE

SLEDD with a L-MOD

Patients randomized to this group will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.

Trial Locations (2)

N6A 5A5

University Hospital, London

N6C 2V4

Victoria Hospital - Critical Care Trauma Centre, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT04353674 - Modulation of Hyperinflammation in COVID-19 | Biotech Hunter | Biotech Hunter